Gene therapy for tuberous sclerosis
US-2024343768-A1 · Oct 17, 2024 · US
Pharmaceutical composition comprising PIBF protein as active ingredient for prevention or treatment of inflammatory disease
US12070487B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-12070487-B2 |
| Application number | US-201917418684-A |
| Country | US |
| Kind code | B2 |
| Filing date | Dec 24, 2019 |
| Priority date | Dec 28, 2018 |
| Publication date | Aug 27, 2024 |
| Grant date | Aug 27, 2024 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to a pharmaceutical composition comprising a progesterone-induced blocking factor (PIBF) protein as an active ingredient for prevention or treatment of inflammatory disease. In the present invention, menopausal asthma animal models have been experimentally identified to decrease airway inflammation when treated with PIBF protein. Thus, the composition can be advantageously used in postmenopausal female asthma patients.
First claim
Opening claim text (preview).
The invention claimed is: 1. A method of treating an asthma in post-menopausal women, comprising: administering or dosing a composition comprising a progesterone-induced blocking factor (PIBF) protein as an active ingredient to a subject. 2. The method of claim 1 , wherein the PIBF protein has a molecular weight of 25 to 45 kDa. 3. The method of claim 1 , wherein the composition further comprises one or more drugs selected from the group consisting of an anti-inflammatory agent, a bronchodilator, an anti-histamine, a decongestant, and an anti-tussive. 4. The method of claim 1 , wherein the composition is formulated into the form of an oral formulation, a preparation for external use, a suppository, or a sterile injectable solution.
Assignees
Inventors
Classifications
Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title
Antiasthmatics · CPC title
having an effect on lung or respiratory system · CPC title
having an effect on the immune system · CPC title
Food compositions, function of food ingredients or processes for food or foodstuffs · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US12070487B2 cover?
- The present invention relates to a pharmaceutical composition comprising a progesterone-induced blocking factor (PIBF) protein as an active ingredient for prevention or treatment of inflammatory disease. In the present invention, menopausal asthma animal models have been experimentally identified to decrease airway inflammation when treated with PIBF protein. Thus, the composition can be advant…
- Who is the assignee on this patent?
- Univ Ulsan Found Ind Coop, Asan Found
- What technology area does this patent fall under?
- Primary CPC classification A61K38/1709. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Aug 27 2024 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).